CoQ10 ubiquinone vs ubiquinol
In the Q-SYMBIO trial, coenzyme Q10 reduced major cardiovascular events in people with chronic heart failure, and that result was statistically significant on the primary long-term outcome. The studied product was the oxidized form, ubiquinone, at 300 mg a day. Ubiquinol is sold as the reduced form. Better absorption on a lab test is not the same as a repeat of Q-SYMBIO. People on warfarin need specific advice before either form.
Labels treat ubiquinol as the upgraded CoQ10. The trial that changed practice used ubiquinone.
Q-SYMBIO
Mortensen and colleagues randomized people with chronic heart failure to coenzyme Q10 or placebo and followed major adverse cardiovascular events (PMID 25282031). The primary long-term outcome favored coenzyme Q10. The dose was 100 mg three times a day, 300 mg total, of ubiquinone, on top of standard heart-failure care. It was not a wellness capsule for people with normal hearts, and it was not a reason to stop prescribed drugs.
What ubiquinol adds
CoQ10 (ubiquinol) is the reduced molecule. Some pharmacokinetic comparisons show higher blood levels from ubiquinol at the same milligram dose. Those comparisons are not outcome trials in heart failure. If you are trying to follow Q-SYMBIO, ubiquinone at the studied dose is the match. If you take warfarin, CoQ10 can affect the INR. That conversation happens with the prescriber, not on a product page.
Sources
- Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014. PMID: 25282031.